

COPY OF ~~PHS~~  
ORIGINAL FILED

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT  
Attorney Docket No.: 021199-000100US

Assistant Commissioner for Patents  
Washington, D.C. 20231

On January 31, 2002

TOWNSEND and TOWNSEND and CREW LLP

By: Joy M. Marshall

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Pollack, William

Application No.: 09/660,862

Filed: September 13, 2000

For: METHOD OF MANUFACTURING  
IMMUNE GLOBULIN

Examiner: V. Ford

Art Unit: 1645

DECLARATION UNDER 37 C.F.R. §  
1.132 OF DR. WILLIAM POLLACK

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

I, William Pollack, Ph.D., being duly warned that willful false statements and the like are punishable by fine or imprisonment or both (18 U.S.C. § 1001), and may jeopardize the validity of the patent application or any patent issuing thereon, state and declare as follows:

1. All statements herein made of my own knowledge are true, and statements made on information or belief are believed to be true and correct.

2. I am currently chairman and chief executive officer of Atopix Pharmaceuticals Corporation, the assignee of the subject application.

3. I, Dr. Pollack, graduated from the Imperial College of Science and Technology at London University with a B.Sc degree in physiology and biochemistry. I received a M.Sc degree in chemistry and physics from the St. Georges Hospital Medical School at London University and a Ph.D. in immunology and immunochemistry from Rutgers University. A copy of my curriculum vitae is attached hereto as Exhibit A.

4. I am the named and true inventor of the above-referenced patent application. I have read and am familiar with the contents of the patent application. In addition, I have read the final Office Action, dated November 2, 2001, received in the present case. It is my understanding that the Examiner believes that the Zolton *et al.* patent, U.S. Patent Number 4,597,966, anticipates the manufacturing method of the present invention. It is also my understanding that the Examiner believes that Zolton *et al.* in combination with either Cheung *et al.*, *Annals of Allergy*, Volume 50, March 1983, 155-160, Sirna, U.S. Patent No. 5,908,827, or Thomas, U.S. Patent No. 4,089,944 makes the invention of the present application obvious.

5. With this application, I claim a method of manufacturing a highly purified IgG4 immune globulin preparation. The method comprises the steps of adjusting

plasma to a pH of about 6.5 and a conductivity of between 3.5-6 millisiemens, and contacting the plasma with an anion exchange resin followed by a cation exchange resin to obtain a final effluent that comprises IgG4 essentially free of other IgG subtypes.

6. The Zolton method, unlike the method of the present application, does not result in an immunoglobulin preparation comprising IgG4 that is essentially free of other IgG subtypes. Zolton's method, instead, results in a purified stable IgG gamma globulin preparation containing all IgG subtypes including IgG1, IgG2, IgG3, and IgG4. In contrast, the present application provides a method of producing a purified IgG4 preparation free from IgG1, IgG2 and IgG3. Zolton's patent teaches a stabilized preparation of IgG (including all subtypes). The present application teaches a method of fractionating IgG into its various subtypes. It is neither suggested nor taught in the Zolton patent that the Zolton purification method results in pure IgG4 (free of all other subtypes), nor, in my opinion, could the purification system described in Zolton result in pure IgG4 free of other IgG subtypes.

7. Zolton's purification method utilizes a QAE-Sephadex anionic resin. In contrast, the present invention uses two resins, an anion exchange resin, e.g., DEAE Sepharose, followed by a cation exchange resin, e.g., CM-Sepharose. The extra fractionation step results in an IgG4 preparation free of other subtypes. Prior to the advent of the present invention, further fractionation of an IgG preparation into a purified IgG4 using chromatographic resins was not known. Again, the present invention provides a facile method of manufacturing IgG4 immune globulin that is essentially free of other IgG subtypes.

8. The purified IgG4 preparation has numerous advantages over an IgG preparation containing all of the IgG subtypes. The purer IgG4 preparation contains less protein and has a higher amount of blocking antibody per unit weight or per unit of protein that is being injected. The intravenous injection of many immune globulin products can lead to reactions that are caused by aggregation and fragmentation of the

immune globulin. The lower protein and higher blocking antibody content of the IgG4 preparation results in a preparation that is safer and more effective than the other less pure IgG preparations that contain IgG1, IgG2 and IgG3 as well as IgG4.

9. Further, the Zolton patent in view of Cheung *et al.*, or Sirna, or Thomas does not make obvious the manufacturing method of the present application, as the secondary references of Cheung *et al.*, Sirna, and Thomas do not address the deficiencies in the Zolton patent.

10. Cheung *et al.* documents a correlation between high IgG4 levels and beekeepers. This correlation, at most, indicates that there may be a role for IgG4 in the protection against anaphylactic reactions. Cheung *et al.* does not teach or suggest how to make a purified IgG4 preparation, or even that a purified IgG4 preparation would be more desirable than a IgG preparation containing all of the IgG subtypes including IgG4.

11. Sirna teaches the use of ion exchange chromatography and high-resolution chromatography to extract purified polypeptide from human urine. I would not expect a purification system for the extraction of polypeptide from *human urine* to be relevant for the purification of *blood plasma* and immunoglobulins. Furthermore, the Sirna method utilizes multiple resins along with DEAE Sepharose and CM-Sepharose. Sirna does not teach or suggest the use of DEAE Sepharose and CM-Sepharose for the purification of IgG4 from human plasma.

12. Thomas teaches how to rapidly solubilize an anti-hemophilic factor composition. The Thomas reference does not teach or suggest how to make a purified IgG4 preparation. Furthermore, Thomas does not teach or suggest fractionation of IgG into an IgG4 fraction.

13. In view of the foregoing, it is my scientific opinion that, after reading the above mentioned references, the presently claimed method is novel and

unobvious over the cited art. One of skill in the art would not be motivated to make the purified IgG4 preparations using the method of the present application. Therefore, Zolton *et al.* does not anticipate this invention and Zolton *et al.* either alone or in combination with either Cheung *et al.*, Sirna, or Thomas does not make the invention of the present application obvious.

The declarant has further nothing to say.

Date: 1/28/02

By: William Pollack  
William Pollack, Ph.D.



**CURRICULUM VITAE  
OF  
DR. WILLIAM POLLACK**

**Education**

Imperial College of Science & Technology. (London University, England).  
B.Sc., A.R.C.S., (Major Chemistry & Physics.)

St. Georges Hospital Medical School. (London University. England).  
M.Sc., (Physiology & Biochemistry). F.R.C.Path., (Clinical Laboratory Pathology).

Rutgers - the State University of New Jersey.  
Ph.D. (Immunology & Immunochemistry). Dissertation thesis: "*A study of the Factors Affecting the Zeta-Potential and Hemagglutination with Human Iso-Antibodies*".

**Relevant Professional Experience**

Played a leading role in the development of Ortho Diagnostic Systems from a small division into a \$200M independent subsidiary company of Johnson and Johnson. Served as Vice President of Research and Development and a Member of the Board of Directors, responsible for administering a R/D budget in excess of \$8M and responsible for the activities of more than 160 individuals, mostly scientists and physicians. Subsequently, at the Purdue Frederick Company, served as Vice President of R/D and Member of the Executive Committee.

Have been responsible for more than 50 new innovative products, including the first immunological pregnancy test and on which all current pregnancy test are based, the first test(s) for hepatitis and various other Human Immune Globulins including those to prevent or treat, Hepatitis, Rubella, Allergies, and Rhesus Disease of the Newborn. In addition, have had considerable manufacturing experience, including cost containment and maximizing gross profit. Also developed a new facility for the manufacture of immune globulins that was based on a novel and vastly simplified process developed under my direction.

Received the Albert and Mary Lasker Award for basic research in Antibody-Mediated-Immune Suppression and for the invention and development of an Immune Globulin to prevent Rhesus Disease of the Newborn, a product (RhoGam™) that has eradicated the disease. In addition, in recognition of this work, received numerous other awards including the John Scott Medal from the City of Philadelphia, The Karl Landsteiner Award from the American Association of Blood Banks, the Joseph Bolivar-DeLee Humanitarian Award of the City of Chicago and the Award from the New York State and the Perinatal Society for Unique Contributions to Maternal and Child Health.

Author of numerous publications, including several contributions to books and a member of many distinguished medical and scientific societies, as well as having served on the Immunological Standards Committee of the World Health Organization.

### ***Professional History***

- |                     |  |
|---------------------|--|
| <b>1985-Present</b> | Atopix Pharmaceuticals Corporation.<br>Carlsbad, California, 92008<br>Chairman & C.E.O.  |
| <b>1981-1985</b>    | The Purdue Frederick Co.<br>Norfolk, Conn. 06856<br>Vice President, R/D<br>Member of Executive Committee.  |
| <b>1956-1981</b>    | Ortho Diagnostics Systems, Inc.<br>Raritan, NJ 08869 (A Johnson & Johnson Co.)<br>Vice President and Member of Board of Directors<br>Director of Research. |
| <b>1954-1956</b>    | Royal Columbian Hospital<br>British Columbia, Canada.<br>Director of Blood Bank & Clinical Laboratories.   |
| <b>1948-1954</b>    | St. Georges Hospital Medical School, London, England   |
| <b>1943-1946</b>    | Royal Navy, Honorable Discharge<br>Lieutenant(RNVR),   |

### ***Academic Appointments***

- 1974-1985** Associate Adjunct Professor.  
University of Medicine & Dentistry of New Jersey.  
(Previously Rutgers Medical School)
- 1968-1981** Associate Clinical Professor of Pathology  
College of Physicians and Surgeons  
Columbia University, New York City, NY.

### ***Awards and Honors***

- 1969** Karl Landsteiner Award of the American  
Association of Blood Banks.
- 1976** John Scott Award, Philadelphia Board of  
Directors of City Trusts.
- 1978** XXXI Annual Gibson Lecturer, Columbia  
Presbyterian Medical Center, New York City.
- 1979** Joseph Bolivar-DeLee Humanitarian Award.  
Chicago, Illinois.
- 1980** Albert and Mary Lasker Clinical Medical Research  
Award.
- 1987** Award from New York State Perinatal Society for  
Unique Contributions to Maternal & Child Health.
- 1980-2002** Listed in: Who's Who in America. Who's Who in  
the World.  
American Men and Women of Science.

***Professional and  
Honorary Societies***

American Association for the Advancement of Science

American Association of Blood Banks

American Association of Immunologists

Harvey Society

New York Academy of Medicine

New York Academy of Science

Sigma Xi

### ***Partial Bibliography***

- 1958** Levine, P, Stroup, M and Pollack, W., *Human Blood Groups*.  
In: *Bacterial and Mycotic Infections in man* by Dubos, R.J. 3rd Ed.
- Pollack, W., Reiss, A.M. and Treacy, M. *Observations on the Direct Coombs Test on Cord Erythrocytes after the Addition of Complement*.  
*Vox Sanguinis* 3: 442-448
- 1959** Hill, G., Pollack, W. and Levine, P. *A Critical Evaluation of a Rapid 'Broad Spectrum' Compatibility Test*. In: International Society of Blood Transfusion Proceedings of the 7th Congress, Rome, 1958, Basel; S. Karger, pp. 341-343
- Pollack, W., Reiss, A.M. and Treacy, M. *The Use of Complement in the Serological Diagnosis of Hemolytic Disease of the Newborn*. In: International Society of Blood Transfusion, Proceedings of the 7th Congress, Rome, 1958. Basel; S. Karger, pp 519-522
- 1960** Hill, G. and Pollack, W. *Evaluation of Antibody Detection Techniques*.  
Int. Soc. Blood Transfusion. 8th Congress, Tokyo, 1960. Basel/New York; S.Karger, pp. 230-232
- 1961** Levine, P., Celano, M., Fenichel, R., Pollack, W. and Singher, H. A "D-Like" Antigen in Rhesus Monkey, Human Rh Positive and Human Rh Negative Red Blood Cells. *J. Immunol.* 87: 747-752
- 1962** Pollack, W., Hager, H.J., and Hollenbeck, L.L. Jr. *The Specificity of Anti-Human Gamma Globulin Reagents*. *Transfusion* 2: 17-30
- 1964** Freda, V.J., Gorman, J.G. and Pollack, W., *Successful Prevention of Experimental Rh Sensitization in Man with an Anti-Rh Gamma Globulin Antibody Preparation*. *Transfusion* 4: 26-32
- Levine, P and Pollack, W., *Hemolytic Disease of the Fetus and Newborn*.  
*Med. Clin. of North America.* 49: 1647-1660
- 1965** Pollack, W., *Some Physico-Chemical Aspects of Hemagglutination*. *Ann. N.Y. Acad. Science* 127: 892-900
- Pollack, W., Hager, H.J., Reckel, R., Toren, D.A., and Singher, H.O. *A Study of the Forces Involved in the Second Stage of Hemmagglutination*.  
*Transfusion.* 5: 158-153
- Robertson, J.G., Freda, V.J. and Pollack. W. *Prevention of Immunization to Rh with Anti- Rh Gamma Globulin*. *Fed. Proc.* 24: 696

- 1965 Cont'** Pollack, W. and Hager, H.J., *A Physico-Chemical Study of Hemagglutination*. Basel/New York; S. Karger. 10th Cong. Int.Soc Blood Transfusion, Stockholm. 1964. pp 802-934
- Gorman, J.G., Freda, V.J., Pollack, W. *Prevention of Isoimmunization to Rh Factor Using High Titer Anti-Rh Gamma Globulin*. Basel/New York; S. Karger. Proc. 10th Cong. Int. Soc. Blood Transfusion, Stockholm. 1964. pp 949-955
- 1966** Freda, V.J., Gorman, J.G., Pollack, W., Robertson. J.G., Jennings, E.R. and Sullivan, J.F. *Prevention of Rh Isoimmunization*. J.A.M.A. 199: 390
- Gorman, J.G., Freda, V.J., Pollack, W. and Robertson, J.G. *Protection from Immunization in Rh-Incompatible Pregnancies. A Progress Report*. Bull. New York Acad. Med. 42: 458-473
- Pollack, W. *The Zeta-Potential and Hemagglutination with Rh Antibodies*. Manual for Workshop on the Techniques Used in Antibody Identification. Am. Assoc. Blood Banks.
- 1967** Pollack, W. and Tripodi, D. *The role of the Immune Response in the Establishment and Rejection of Neoplastic Tissue*. Int. Arch. Allergy and Immunol. 32: 429-436
- Freda, V.J., Gorman, J.G. and Pollack, W. *Suppression of Primary Rh Immune Response with Passive Rh Immune Globulin*. N.E.J.M. 277: 1022
- 1968** Pollack, W., Gorman, J.G., Freda, V.J., Jennings, E.R. and Sullivan, J.F. *Clinical Evaluation of Rh Immune Globulin in the Prophylaxis of Immunization to the Rh Factor*. Proc. 11th Cong. Int. Soc. Blood Transfusion, Sydney 1966 Bibl. Haemat. 29: 231-236
- Jennings, E.R., Dibbern, H.H., Hodell, F.H., Monroe, C., Peckham, N.H., Sullivan, J.F. and Pollack, W. *Long Beach ( California) Experience with Rh Immune Globulin*. Transfusion. 8: 146-148
- Pollack, W., Singher, H.O., Gorman, J.G. and Freda, V.J. *The Prevention of Isoimmunization to the Rh Factor by Passive Immunization with Rh<sub>0</sub>(D) Immune Globulin (Human)*. Haematologia. 2: No.1: pp.1-8
- Pollack, W., Gorman, J.G. and Freda, V.J. *Prevention of Rh Hemolytic Disease*. Progress in Hematology. VII
- Pollack, W., Gorman, J.G., Freda, V.J., Ascari, W.Q. and Allen, A.E. *Results of Clinical Trials Of RhoGam™ in Women*. Transfusion. 8: 151-153

- 1969** Jennings, E.R., Dibbern, H.H., Hodell, F.H., Monroe, C.H., Peckham, N.H., Sullivan, J.F. and Pollack, W. *Prevention of Rh Hemolytic Disease of the Newborn*. California Medicine, 110:
- Ascarì, W.Q., Levine, P. and Pollack, W. *Incidence of Maternal Rh Immunization by ABO Compatible and Incompatible Pregnancies*. Brit. Med. J. 1: 399-401
- 1970** Tripodi, D., Hollenbeck, L. and Pollack, W. *The effect of Endotoxin on the Implantation of a Mouse Sarcoma*. Int. Arch. of Allergy and Immunol. 37: 557-585
- Pollack, W. and Kochesky, R.J. *The Importance of Antibody Concentration Binding Constant and Heterogeneity in the Suppression of Immunity to the Rh Factor*. Int. Arch. Allergy and Immunol. 38: 410-415
- Pollack, W. and Reckel, R.P. *The Zeta-Potential and Hemagglutination with Rh Antibodies*. Int. Arch. of Allergy and Immunol. 38: 417-421
- 1971** Tripodi, D., Weis, J., Bonness, P.E. and Pollack, W. *Identification of Platelet Orosmuroid*. Transfusion 11: 139-144
- Pollack, W., Ascari, W.Q., Kochesky, R.J., O'Connor, R.R., Ho, T. and Tripodi, D. *Studies on Rhesus Prophylaxis with Rh Positive Blood*. No.1 Transfusion. 2: 333-339
- 1972** Pollack, W. *Rh Immune Globulin Administered to D<sup>u</sup>-Positive Mother: No Adverse Effect*. J.A.M.A. 221: No. 12
- Tripodi, D., Redeker, A., McKee, A.P., and Pollack, W. *Comparative Clinical Evaluation of H.A.A. Detection Among Liver Disease Patients*. Int. Arch. of Allergy and Immunol. 42: 681-685
- Tripodi, D., Gocke, D.J., McKee, A.P., Hawk, J., Campbell, J. and Pollack, W. *No.1. A comparative Clinical Evaluation of H.A.A Detection. No. 2. H.A.A Detection Among Blood Donors*. Transfusion. 12: 109-110
- 1973** Levine, P., Tripodi, D., Struck, J., Zmijewski, C.M. and Pollack, W. *Hemolytic Anemia Associated with Rh Null but not with Bombay Blood*. Vox. Sang. Suppl. 24: 80-83
- McKee, A.P., Pollack, W. and Tripodi, D. *Low Voltage Counterimmuno-electrophoreses for the Detection of Australia Antigen*. Vox. Sang. Suppl. 24: 80-83
- 1975** Freda, V.J., Gorman, J.G., Pollack, W. and Bowe, E. *Prevention of Rh Hemolytic Disease - Ten Years Clinical Experience with Rh Immune Globulin*. N.E.J.M. 293

- 1975 Cont'** Rancourt, M.W., McKee, A.P. and Pollack, W. *Mitochondrial Profile of a Mammalian Lymphocyte*. Ultrastructure Res. 51: 418-424
- Redeker, A.G., Moseley, J.W., Gocke, D.J., McKee, A.P. and Pollack, W. *Hepatitis B Immune Globulin as a Prophylactic Measure for Spouses Exposed to Type B Hepatitis*. N.E.J.M. 293: 1055-1059
- 1976** Keith, L., Burger, G.S. and Pollack, W. *The Transfusion of Rh Negative Women*. Amer. J. Obs. Gyn. 125: 502
- Reiss, A.M. and Pollack, W. *Detection and Semiquantitation of Fetal Cells (Fetal Hemoglobin) in the Maternal Circulation*. Man. Clin Immunol.
- Pollack, W. and Reckel, R.P. *A Reappraisal of the Zeta-Potential Model of Hemagglutination*. 5th Int. Convocation. Immunol., Buffalo, N.Y. 17-26
- 1977** Ratliff, E.A., Pollack, W., Tripodi, D. and Ho, T. *Solid Phase Radioimmune Assay for Quantitating Anti-HBs in Hepatitis B Immune Globulin*. Int. Arch. of Allergy and Immunol. 4: 231-237
- Pollack, W. and Reckel, R.P. *A Reappraisal of the Forces Involved in Hemagglutination*. Int. Arch. of Allergy and Immunol. 54: 231-237
- Freda, V.J., Gorman, J.G. and Pollack, W. *Prevention of Rh Hemolytic with Rh Immune Globulin*. Am. J. Obs. Gyn. 128: 456-460
- 1978** Gorman J.G., Rincon, F.J., Freda, V.J. and Pollack, W. *Closing the Utilization Gap on Rh Immune Globulin*. Med. Lab. Obs. March. p 199
- Freda, V.J., Pollack, W. and Gorman, J.G. *Rh Disease: How Near the End?* Hospital Practice. June. pp 61-69
- 1981** Pollack, W. *Rh Hemolytic Disease of the Newborn: Its Cause and Prevention*. Reproductive Immunology 70: 185-203
- Reckel, R.P., Harris, J., Botsko, E. and Pollack, W. *A new Capillary Tube Agglutination-Inhibition Test for the Detection of Circulating Immune Complexes Containing Endogenously Bound C1q*. Immunol. Letters. 3: 107
- 1982** Pollack, W. *Recent Understanding for the Mechanism by which Passively Administered Rh Antibody Suppresses the Immune Response to the Rh Antigen in Unimmunized Rh Negative Women*. Clin. Obs. and Gyn. 25:255
- 1984** Pollack, W. *Mechanism of Rh Immune Suppression by Rh Immune Globulin*. 37th Annual Meeting, A.A.B.B.. San Antonio. Texas.

**1985**

Pollack, W. and Iny, O. *A Physico-Chemical Study of PVPI Solutions Leading to Reformulation of Betadine Preparations ( 5% PVPI)*. J. Hosp. Infections 6: Supplement

Gocke, D.J., Ponticas, S. and Pollack W. *In Vitro Studies of the Killing of Clinical Isolates by Povidone-Iodine Solutions*. J. Hosp. Infection 6: 59